EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Survival rate for different TNF-antagonists in the treatment of different immune mediated inflammatory diseases



Survival rate for different TNF-antagonists in the treatment of different immune mediated inflammatory diseases








(PDF emailed within 1 workday: $29.90)

Accession: 021838521

Download citation: RISBibTeXText



Related references

Adequacy of initiating TNF antagonists within 3 weeks of starting latent tuberculosis infection treatment in patients with immune-mediated inflammatory diseases. Infectious Diseases (): 1-6, 2015

Indications and modes of use for interleukin (IL)-1 antagonists in inflammatory dermatosis: a new therapeutic approach to immune-mediated inflammatory diseases. Annales de Dermatologie et de Venereologie 139(6-7): 459-467, 2012

Gender and the treatment of immune-mediated chronic inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease and psoriasis: an observational study. Bmc Medicine 10: 82-82, 2012

Treatment of T-helper cell type 2-mediated immune diseases by retinoid antagonists. Official Gazette of the United States Patent & Trademark Office Patents 1273(4), Aug 26, 2003

Recent Advances in the Treatment of Immune-Mediated Inflammatory Diseases. Methods in Molecular Biology 1371: 143-155, 2016

Triptolide in the treatment of psoriasis and other immune-mediated inflammatory diseases. British Journal of Clinical Pharmacology 74(3): 424-436, 2013

Autoimmunity: break-through in the diagnosis and treatment of immune-mediated inflammatory diseases. Immunology Letters 162(2 Pt B): 150-162, 2015

RORγt Modulators Are Potentially Useful for the Treatment of the Immune-Mediated Inflammatory Diseases. Acs Medicinal Chemistry Letters 5(8): 844-845, 2014

A Systematic Review of Factors Associated with Non-Adherence to Treatment for Immune-Mediated Inflammatory Diseases. Advances in Therapy 32(11): 983-1028, 2016

Anti-TNF-α agents in the treatment of immune-mediated inflammatory diseases: mechanisms of action and pitfalls. ImmunoTherapy 2(6): 817-833, 2011

Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003). Annals of the Rheumatic Diseases 62 Suppl 2: Ii2-Ii9, 2003

TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflammation & Allergy-Drug Targets 6(4): 223-235, 2007

TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflammation & Allergy Drug Targets 6(4): 223-235, 2008

Impact of Treatment-Related Beliefs on Medication Adherence in Immune-Mediated Inflammatory Diseases: Results of the Global ALIGN Study. Advances in Therapy (): -, 2016

Immune-mediated inflammatory diseases in patients with inflammatory bowel disease. Baseline data from the Aquiles study. Gastroenterologia Y Hepatologia 37(9): 495-502, 2014